Long-term outcome of Crohn's disease following corticosteroid-induced remission

American Journal of Gastroenterology

Volumn 102, Issue 4, 2007, Pages 814-819

  Papi, Claudio ^a   Festa, Virginia ^a   Leandro, Gioacchino ^b   Moretti, Alessandra ^a   Tanga, Monica ^a   Koch, Maurizio ^a   Capurso, Lucio ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; C REACTIVE PROTEIN; CORTICOSTEROID; PREDNISONE;

ADULT; ARTICLE; CLINICAL OBSERVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COVARIANCE; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG INDICATION; FEMALE; FOLLOW UP; GENDER; GROUPS BY AGE; HEALTH BEHAVIOR; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RATING SCALE; RELAPSE; REMISSION; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33947655965     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01055.x     Document Type: Article

References (28)

1. Munkolm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
2. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2002;123:393-5.
3. Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative Crohn's disease study: Results of drug treatment. Gastroenterology 1979;77:847-69.
4. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): Results of drug treatment. Gastroenterology 1984;86:249-66.
5. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-8.
6. Rutgeerts PJ. The limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001;15:1515-25.
7. Steinhart A, Ewe K, Griffiths A, et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003;(4):CD000301.
8. Plevy SE. Corticosteroid-sparing treatments in patients with Crohn's disease. Am J Gastroenterol 2002;97:1607-17.
9. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol. 2002;97:803-23.
10. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2):CD000545.
11. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2):CD000067.
12. Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: A prospective, randomizd clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992;102:1647-53.
13. Beaugerie L, Seksik P, Niom-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6.
14. Hanauer S. Considerations in the management of steroid dependent Crohn's disease. Gastroenterology 2003;125:906-10.
15. Franchimont DP, Louis E, Croes F, et al. Clinical pattern of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol 1998;10:821-5.
16. Reinisch W, Gasche C, Wyatt J, et al. Steroid dependency in Crohn's disease. Lancet 1995;345:859.
17. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 1991;6:192-219.
18. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review. Gut 2002;50:485-9.
19. Nielsen OH, Vainer B, Rask-Madsen J. Review article: The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001;15:1699-1708.
20. American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease. Gastroenterology 2006;130:940-87.
21. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53:1-16.
22. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
23. Siproudhis L, Mortaji A, Mary JY, et al. Anal lesions: Any significant prognosis in Crohn's disease? Eur J Gastroenterol Hepatol 1997;9:239-43.
24. Gelbmann CM, Rogler G, Gross V, et al. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease. Am J Gastroenterol 2002;97:1438-45.
25. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988;10:401-5.
26. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661-5.
27. Arnott IDR, Watts D, Ghosh S. Review article: Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther 2002;16:857-67.
28. Consigny Y, Modigliani R, Colombel JF, et al. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006;12:551-7.